Serious events with infliximab in patients with inflammatory bowel disease: A 9-year cohort study in the Netherlands

Drug Safety

Volumn 31, Issue 12, 2008, Pages 1135-1144

  De Vries, Hilbert S ^a   Van Oijen, Martijn G H ^a   De Jong, Dirk J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Inflammatory bowel disease; Infliximab, adverse reactions; Tumour necrosis factor alpha inhibitors, adverse reactions

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE;

ADULT; ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; CARCINOID; COHORT ANALYSIS; COLORECTAL CARCINOMA; DISEASE DURATION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENTERITIS; FEMALE; FOLLOW UP; GASTROENTERITIS; GASTROINTESTINAL SURGERY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MELANOMA; MORTALITY; NETHERLANDS; PATIENT MONITORING; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SIGNET RING CARCINOMA; SKIN CARCINOMA; SMALL INTESTINE CARCINOMA; SQUAMOUS CELL CARCINOMA; URINARY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; CAUSALITY; COHORT STUDIES; FEMALE; GASTROINTESTINAL AGENTS; HOSPITALIZATION; HUMANS; INFLAMMATORY BOWEL DISEASES; LENGTH OF STAY; MALE; NEOPLASMS; NETHERLANDS; RETROSPECTIVE STUDIES; SURGICAL PROCEDURES, OPERATIVE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 56749151619     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/0002018-200831120-00009     Document Type: Article

References (35)

1. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134 (2): 577-94
2. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448 (7152): 427-34
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359 (9317): 1541-9
4. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117 (4): 761-9
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353 (23): 2462-76
6. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369 (9573): 1641-57
7. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999; 13: 16-22
8. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 2005; 44 (6): 714-20
9. Salvana EMT, Cooper GS, Salata RA. Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients. J Infect 2007; 55 (6): 484-7
10. Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007; 52 (6): 1481-4
11. Cohen RD, Bowie WR, Enns R, et al. Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease. Thorax 2007; 62 (11): 1013-4
12. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295 (19): 2275-85
13. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44 (2): 265-7
14. van Berge Henegouwen GP. Consensus for infliximab treatment of patients with Crohn's disease. Ned Tijdschr Geneeskd 2000; 144 (38): 1844-5
15. Hommes DW, Oldenburg B, van Bodegraven AA, et al. Guidelines for treatment with infliximab for Crohn's disease. Neth J Med 2006; 64 (7): 219-29
16. Baert F, Noman M, Vermoire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348 (7): 601-8
17. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55 (6): 749-53
18. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98 (6): 1315-24
19. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) [online]. Available from URL: http://ctep.cancer.gov/forms/ CTCAEv3.pdf [Accessed 2008 Oct 2]
20. WHO-Uppsala Monitoring Centre (UMC) scale of case causality assessment [online]. Available from URL: http://www.who-umc.org/graphics/4409.pdf [Accessed 2008 Oct 2]
21. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002; 97 (12): 2962-72
22. de Vries HS, van Oijen MG, van Hoven-van Loo KE, et al. Monitoring vital signs during infusion with infliximab does neither indicate nor predict development of acute infusion reactions. J Clin Gastroenterol. In press
23. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350 (9): 876-85
24. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53 (6): 849-53
25. Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126 (1): 19-31
26. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4 (5): 621-30
27. Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134 (4): 929-36
28. Xie JL, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol 2008; 14 (3): 378-89
29. Lutgens MW, van der Heijden GJ, Vleggaar FP, et al. A comprehensive meta-analysis of the risk of colorectal cancer in ulcerative colitis and Crohn's disease. Gastroenterology 2008; 134 (4): A33-4
30. Zisman TL, Rubin DT. Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol 2008; 14 (17): 2662-9
31. Johnson FR, Ozdemir S, Mansfield C, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007; 133 (3): 769-79
32. Jess T, Winther KV, Munkholm P, et al. Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology 2002; 122 (7): 1808-14
33. Loftus EV, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1998; 114 (6): 1161-8
34. Lichtenstein GR, Yan SK, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128 (4): 862-9
35. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf 2000; 23 (5): 429-48